1-15 of 15
George Somlo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer

Free
Brooke Felsheim, Aranzazu Fernandez Martinez, Cheng Fan, Adam Pfefferle, Michele Hayward, Katherine Hoadley, Naim Rashid, Sara Tolaney, George Somlo, Lisa Carey, William Sikov, Charles Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): GS3-10.
https://doi.org/10.1158/1557-3265.SABCS24-GS3-10
Published: 13 June 2025
View articletitled, Abstract GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer
Journal Articles

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

Available to Purchase
Halle C.F. Moore, William E. Barlow, George Somlo, Julie R. Gralow, Anne F. Schott, Daniel F. Hayes, Peter Kuhn, James B. Hicks, Lisa Welter, Philip A. Dy, Christina H. Yeon, Alison K. Conlin, Ernie Balcueva, Danika L. Lew, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 611–617.
https://doi.org/10.1158/1078-0432.CCR-21-3131
Published: 15 February 2022
View articletitled, A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
Open the PDF for A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222 in another window
Includes: Supplementary data
Journal Articles

Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis

Free
Liang Liu, Lin Yang, Wei Yan, Jing Zhai, Donald P. Pizzo, Peiguo Chu, Andrew R. Chin, Meng Shen, Chuan Dong, Xianhui Ruan, Xiubao Ren, George Somlo, Shizhen Emily Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2370–2382.
https://doi.org/10.1158/1078-0432.CCR-17-2545
Published: 14 May 2018
View articletitled, Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis
Open the PDF for Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis in another window
Includes: Supplementary data
Journal Articles

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

Free
George Somlo, Paul H. Frankel, Banu K. Arun, Cynthia X. Ma, Agustin A. Garcia, Tessa Cigler, Leah V. Cream, Harold A. Harvey, Joseph A. Sparano, Rita Nanda, Helen K. Chew, Timothy J. Moynihan, Linda T. Vahdat, Matthew P. Goetz, Jan H. Beumer, Arti Hurria, Joanne Mortimer, Richard Piekarz, Sharon Sand, Josef Herzog, Lily R. Van Tongeren, Katherine V. Ferry-Galow, Alice P. Chen, Christopher Ruel, Edward M. Newman, David R. Gandara, Jeffrey N. Weitzel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4066–4076.
https://doi.org/10.1158/1078-0432.CCR-16-2714
Published: 01 August 2017
View articletitled, Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Open the PDF for Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083 in another window
Includes: Supplementary data
Journal Articles

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

Free
Roisin M. Connolly, Huili Li, Rachel C. Jankowitz, Zhe Zhang, Michelle A. Rudek, Stacie C. Jeter, Shannon A. Slater, Penny Powers, Antonio C. Wolff, John H. Fetting, Adam Brufsky, Richard Piekarz, Nita Ahuja, Peter W. Laird, Hui Shen, Daniel J. Weisenberger, Leslie Cope, James G. Herman, George Somlo, Agustin A. Garcia, Peter A. Jones, Stephen B. Baylin, Nancy E. Davidson, Cynthia A. Zahnow, Vered Stearns
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2691–2701.
https://doi.org/10.1158/1078-0432.CCR-16-1729
Published: 31 May 2017
View articletitled, Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Open the PDF for Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study in another window
Includes: Supplementary data
Journal Articles

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Free
Vinay Varadan, Hannah Gilmore, Kristy L.S. Miskimen, David Tuck, Shikha Parsai, Amad Awadallah, Ian E. Krop, Eric P. Winer, Veerle Bossuyt, George Somlo, Maysa M. Abu-Khalaf, Mary Anne Fenton, William Sikov, Lyndsay N. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3249–3259.
https://doi.org/10.1158/1078-0432.CCR-15-2021
Published: 30 June 2016
View articletitled, Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
Open the PDF for Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

Free
George Somlo, Francesco Atzori, Lewis C. Strauss, William J. Geese, Jennifer M. Specht, William J. Gradishar, Alissa Rybicki, Oumar Sy, Linda T. Vahdat, Javier Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1884–1893.
https://doi.org/10.1158/1078-0432.CCR-12-0652
Published: 02 April 2013
View articletitled, Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Open the PDF for Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 in another window
Includes: Supplementary data
Journal Articles

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

Free
George Somlo, Ricardo Spielberger, Paul Frankel, Chatchada Karanes, Amrita Krishnan, Pablo Parker, Leslie Popplewell, Firoozeh Sahebi, Neil Kogut, David Snyder, An Liu, Timothy Schultheiss, Stephen Forman, Jeffrey Y. C. Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (1): 174–182.
https://doi.org/10.1158/1078-0432.CCR-10-1912
Published: 04 January 2011
View articletitled, Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
Open the PDF for Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma in another window
Journal Articles

Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines

Free
Long Gu, Sean K. Lau, Sofia Loera, George Somlo, Susan E. Kane
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7196–7206.
https://doi.org/10.1158/1078-0432.CCR-09-0585
Published: 30 November 2009
View articletitled, Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines
Open the PDF for Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

Free
Thehang H. Luu, Robert J. Morgan, Lucille Leong, Dean Lim, Mark McNamara, Jana Portnow, Paul Frankel, David D. Smith, James H. Doroshow, David R. Gandara, Ana Aparicio, George Somlo, Carol Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7138–7142.
https://doi.org/10.1158/1078-0432.CCR-08-0122
Published: 03 November 2008
View articletitled, A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Open the PDF for A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study in another window
Journal Articles

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Free
Robert J. Morgan, Jr., Timothy W. Synold, Bixin Xi, Dean Lim, Stephen Shibata, Kim Margolin, Roderich E. Schwarz, Lucille Leong, George Somlo, Przemyslaw Twardowski, Yun Yen, Warren Chow, Merry Tetef, Paul Lin, Benjamin Paz, Mariana Koczywas, Lawrence Wagman, David Chu, Paul Frankel, Susan Stalter, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1232–1237.
https://doi.org/10.1158/1078-0432.CCR-06-1735
Published: 22 February 2007
View articletitled, Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Open the PDF for Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity in another window
Journal Articles

Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine

Free
Harry Openshaw, Karen Beamon, Timothy W. Synold, Jeff Longmate, Neal E. Slatkin, James H. Doroshow, Stephen Forman, Kim Margolin, Robert Morgan, Stephen Shibata, George Somlo
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (2): 461–467.
https://doi.org/10.1158/1078-0432.CCR-0772-03
Published: 03 February 2004
View articletitled, Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine
Open the PDF for Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine in another window
Journal Articles

Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics

Free
Robert J. Morgan, Jr., James H. Doroshow, Timothy Synold, Dean Lim, Stephen Shibata, Kim Margolin, Roderich Schwarz, Lucille Leong, George Somlo, Przemyslaw Twardowski, Yun Yen, Warren Chow, Paul Lin, Benjamin Paz, David Chu, Paul Frankel, Susan Stalter
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5896–5901.
Published: 15 December 2003
View articletitled, Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics
Open the PDF for Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics in another window
Journal Articles

Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies

Free
Merry L. Tetef, Timothy W. Synold, Warren Chow, Lucille Leong, Kim Margolin, Robert Morgan, James Raschko, Stephen Shibata, George Somlo, Yun Yen, Susan Groshen, Kay Johnson, Heinz-Josef Lenz, David Gandara, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (6): 1569–1576.
Published: 01 June 2001
View articletitled, Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies
Open the PDF for Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies in another window
Journal Articles

Initial Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembryonic Antigen Antibody and Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-producing Metastatic Breast Cancer

Free
Jeffrey Y. C. Wong, George Somlo, Tamara Odom-Maryon, Lawrence E. Williams, An Liu, Dave Yamauchi, Anna M. Wu, Paul Yazaki, Sharon Wilczynski, John E. Shively, Stephen Forman, James H. Doroshow, Andrew A. Raubitschek
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 3224s–3231s.
Published: 01 October 1999
View articletitled, Initial Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembryonic Antigen Antibody and Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-producing Metastatic Breast Cancer
Open the PDF for Initial Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembryonic Antigen Antibody and Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-producing Metastatic Breast Cancer in another window